Search
 

An Obamacare about-face for UnitedHealth? Don't laugh!

Odd as it may seem, given how well the decision to bail on the ACA has paid off, UnitedHealth should at least consider an eventual return.

By Max Nisen | Updated on July 19, 2017
Now that Obamacare looks like it might stick around a little while longer, maybe UnitedHealth Group Inc. should reconsider abandoning it. Photo: AP

(Bloomberg Gadfly) Now that Obamacare looks like it might stick around a little while longer, maybe UnitedHealth Group Inc. should reconsider abandoning it. Of course, the insurer’s solid second-quarter results reported on Tuesday — it beat analyst earnings expectations and boosted full-year guidance — benefited from its retreat from the Affordable Care Act’s (ACAs) individual exchanges. 

But odd as it may seem, given how well the decision to bail on the ACA has paid off, UnitedHealth should at least consider an eventual return. Getting out was arguably the right choice for the company last year. But if done right, returning could be a good idea, too. 

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Recommended Stories

FTC sues UnitedHealth, Cigna, and CVS over high insulin prices

FTC sues UnitedHealth, Cigna, and CVS over high insulin prices

Maydeen Merino |

“Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful PBMs and their greed,” said Rahul Rao, deputy director of the FTC’s Bureau of Competition.

BenefitsPRO Broker Expo 2025 (BPRO)Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information
 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2024 ALM Global, LLC. All Rights Reserved.